Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics Inc. for Oral Interleukin23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease

HORSHAM Pa. May 30 2017 PRNewswire Janssen Biotech Inc. one of the Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has entered into a worldwide exclusive license and collaboration agreement with Protagonist Therapeutics In...